Esperion Therapeutics, Inc. (ESPR)
Valuation Overview•Is Esperion Therapeutics, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 46/100, reflecting stable operating margins and manageable leverage.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Average quality business weighed down by significant solvency concerns.
Wall Street sentiment is generally neutral. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
ESPR demonstrates adequate business quality with stable profitability. However, this is severely offset by a highly leveraged balance sheet (Debt/EBITDA > 4.0x) and elevated financial risk.
The company is driving exceptional top-line expansion (74.8% 3Y CAGR) paired with stable bottom-line earnings. The company maintains healthy operational efficiency with a 18.1% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $80.1M | +21.3% | +74.8% | +12.1% | — | |
| EBITDA | -$6.6M | — | — | — | — | |
| Net Income | -$25.2M | +56.2% | +54.0% | — | +7.6% | |
| EPS (Diluted) | $-0.10 | +60.7% | — | — | +26.1% | |
| Free Cash Flow | -$27.9M | +45.4% | +57.8% | +33.2% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 65.0% | 70.0% | 71.3% | 81.9% |
| Operating Margin | 18.1% | -34.1% | -125.9% | -107.0% |
| Net Margin | -1.8% | -67.0% | -170.7% | -136.5% |
| FCF Margin | -4.3% | -42.3% | -139.0% | -108.4% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.04 | $-0.10 | -150.0% | ||
| Q2'26 | $-0.04 | $-0.01 | +75.0% | ||
| Q1'26 | $0.23 | $0.22 | -4.3% | ||
| Q4'25 | $-0.09 | $-0.16 | -77.8% | ||
| Q3'25 | $-0.17 | $-0.02 | +88.2% | ||
| Q2'25 | $-0.18 | $-0.21 | -16.7% | ||
| Q1'25 | $-0.14 | $-0.10 | +28.6% | ||
| Q4'24 | $-0.14 | $-0.15 | -7.1% |
Total return is +186.4% (1Y), outperforming the benchmark by +161.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -15.1% | -24.4% | — |
| 1Y | +186.4% | +161.4% | — |
| 3YCAGR | +27.2% | +7.9% | — |
| 5YCAGR | -33.8% | -46.2% | — |
| 10YCAGR | -15.7% | -28.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Esperion Therapeutics, Inc. (ESPR) valuation, health, and returns.
Based on peer relative multiples, Esperion Therapeutics, Inc. appears Limited: Cheap versus peers compared to industry peers.
Esperion Therapeutics, Inc. has multiple valuation anchors: Peer Relative Fair Value: $4.31 | Wall Street Analyst Target: $3.19 (implying +1.3% upside). A convergence of these signals offers higher conviction.
Esperion Therapeutics, Inc. displays fair financial health with a composite quality score of 46/100, supported by a Altman Z-Score of -4.6 (distress zone), Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of 66.5%.
Esperion Therapeutics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Esperion Therapeutics, Inc.'s current growth trajectory is Decelerating. The company achieved +21.3% 1Y revenue growth and +60.7% 1Y EPS growth, compared to its 3Y revenue CAGR of +74.8%.
Wall Street consensus is Hold based on 25 analysts, beating EPS expectations in 58% of recent quarters with a -1-quarter streak. The consensus price target represents a +1.3% change from current levels.
Investment risks for Esperion Therapeutics, Inc. include: -53.2% 1-year max drawdown, high beta (1.92x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 1.92x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.